<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04062500</url>
  </required_header>
  <id_info>
    <org_study_id>GREARTWAL</org_study_id>
    <nct_id>NCT04062500</nct_id>
  </id_info>
  <brief_title>Registry for Longitudinal Mortality and Therapy in Patients With Heart Failure</brief_title>
  <acronym>GREARTWAL</acronym>
  <official_title>Registry for Longitudinal Mortality and Therapy in Patients With Heart Failure (GREARTWAL Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai 10th People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>First Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Chao Yang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Hospital of China Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yangpu District Central Hospital Affiliated to Tongji University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xuhui Central Hospital, Shanghai</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ningbo Medical Center Lihuili Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shaanxi University of Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>People's Hospital of Xinjiang Uygur Autonomous Region</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Zhengzhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai 10th People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this registry is to compile a large clinical database on the medical
      management of patients hospitalized with acute heart failure, using information collected
      from hospitals across China.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Registry for Longitudinal mortality and therapy in patients with Heart Failure is a large,
      multicenter, prospective, open-label registry of the management of patients treated in the
      hospital for acute heart failure in China. The objective of this study is to investigate the
      clinical features and prognosis of patients with heart failure, and discover the
      characteristics of high-risk heart failure patients, and elucidate critical factors which
      predict the development and outcomes of symptomatic heart failure patients.

        1. To elucidate the clinical characteristics and prognostic risks of patients with heart
           failure.

        2. To study the characteristics of high-risk heart failure patients and predict the key
           factors for the development of symptomatic heart failure patients.

        3. To elucidate the compliance of patients with heart failure and the incidence of adverse
           drug effects.

        4. To investigate the effect of self-management on outcomes in patients with heart failure.

        5. To elucidate critical factors associated with the development and outcomes of heart
           failure.

        6. To investigate hospitalization expenses for heart failure.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2027</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality of acute decompensated heart failure</measure>
    <time_frame>10 years</time_frame>
    <description>In-hospital and Annual mortality</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Re-hospitalization rate</measure>
    <time_frame>10 years</time_frame>
    <description>Re-hospitalization of acute decompensated heart failure</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">10500</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Patients with heart failure</arm_group_label>
    <description>patients treated in the hospital for acute heart failure in China</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Mortality and Rehospitalization rate</intervention_name>
    <description>Mortality and Re-hospitalization of acute decompensated heart failure</description>
    <arm_group_label>Patients with heart failure</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Human serum from enrolled patients
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with heart failure
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - 1. 18 years and older. 2. Meet the diagnostic criteria of China 2018 or JACC/AHA 2017 or
        ESC 2016 heart failure guidelines.

        3. Agree to be tested and sign an informed consent certificate.

        Exclusion Criteria:

          -  1. Age&lt;18 years old. 2. Patients who refused to participate. 3. Patients may have a
             life expectancy of less than 1 years due to non- heart failure clinical conditions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Dachun Xu, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Tenthth People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dachun Xu, PhD</last_name>
    <phone>18917684045</phone>
    <phone_ext>+86</phone_ext>
    <email>xdc77@tongji.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Tenth People's Hospital, Tongji University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200072</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dachun Xu, MD,PhD</last_name>
      <phone>+86 18917684045</phone>
      <email>xdc77@tongji.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Yawei Xu, MD,PhD</last_name>
      <phone>+86 13916698181</phone>
      <email>xuyawei@tongji.edu.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 9, 2019</study_first_submitted>
  <study_first_submitted_qc>August 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2019</study_first_posted>
  <last_update_submitted>August 19, 2019</last_update_submitted>
  <last_update_submitted_qc>August 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai 10th People's Hospital</investigator_affiliation>
    <investigator_full_name>Ya-Wei Xu</investigator_full_name>
    <investigator_title>MD, pHD, Director of Cardiovascular Department</investigator_title>
  </responsible_party>
  <keyword>Heart Failure,prognostic, registry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

